Comparison of two dosages of rabbit antithymocyte globulin (r-ATG) in treating children with severe aplastic anemia.

Abstract	In this study, efficacy and safety of two different dosages of rabbit antithymocyte globulin (r-ATG) combined with cyclosporine (CsA) in treating children with severe aplastic anemia (SAA) were compared. The clinical data of 122 SAA children treated by r-ATG/CsA between Jan 2005 and Jan 2017 at Sun Yat-sen Memorial Hospital of Sun Yat-sen University were retrospectively analyzed. The r-ATG dose of 55 cases was 2.5mg/(kg·d, group 1), and in the other 67 cases it was 3.5 mg/(kg·d, group 2). r-ATG was continuously administered for 5 days. In the 3rd and 6th month after treatment, the efficacy rate of group 2 was higher than that of group 1 (45.5% vs 26.4%, P=0.032; 54.5% vs 35.8%, P=0.042). In the 9th and 12th month after treatment, the efficacy rates of both groups were similar (71.2% vs 54.9%, P=0.077; 75.9% vs 68.6%, P=0.399). The incidence rates of serum diseases (74.5% vs 79.1%, P=0.551), short-term infection rates (76.4% vs 62.7%, P=0.105), early mortality (3.6% vs 1.5%, P=0.447), and 3-year overall survival rates (89.5% vs 90.1%, P=0.932) of both groups showed no significant differences. The r-ATG/CSA therapy was safe and effective towards SAA. The final efficacies and safety of the two r-ATG dosages were equal. However, the follow-up period in this study was relatively short, so the intergroup comparison of the long-term complications and survival rates needed to be further followed up.
Authors	Shao-Fen Lin, Su Liu, Hong-Man Xue, Jun-Bin Huang, Jian Wang, Qi-Hui Chen, Bi-Hong Zhang, Chun Chen
Journal	Die Pharmazie (Pharmazie) Vol. 73 Issue 5 Pg. 264-268 (05 01 2018) ISSN: 0031-7144 [Print] Germany
PMID	29724291 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antilymphocyte Serum Cyclosporine thymoglobulin
Topics	Adolescent Anemia, Aplastic (drug therapy) Antilymphocyte Serum (administration & dosage, adverse effects) Child Cyclosporine (administration & dosage, adverse effects) Dose-Response Relationship, Drug Female Humans Male Recurrence Retrospective Studies Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!